**Supplemental Table 1.** Immune-Related Response Criteria Versus RECIST v1.1

|  |  |  |
| --- | --- | --- |
| **Category** | **Immune-related response criteriaa,b** | **RECIST v1.1b,c** |
| Measurement of tumor burden | * Bidimensional
 | * Unidimensional
 |
| Complete response | * Disappearance of all target and non-target lesions
* Nodes must regress to <10 mm short axis
* No new lesions
* Confirmation required
 |
| Partial response (PR) | * ≥50% decrease in tumor burden compared with baselined
* Confirmation required
 | * ≥30% decrease in tumor burden compared with baseline
* Confirmation required
 |
| Progressive disease (PD) | * **≥**25% increase in tumor burden compared with baseline, nadir, or “reset” baselined
* New lesions added to tumor burden
* Confirmation required
 | * ≥20% + 5 mm absolute increase in tumor burden compared with nadir
* Appearance of new lesions or progression of non-target
 |
| Stable disease  | * Neither PR nor PD
 |

aCompiled from Wolchok et al. [67]

bCompiled from Hodi et al. [68]

cCompiled from Eisenhauer et al. [71]

dIf an increase in tumor burden is observed at the first scheduled assessment, baseline is reset to the value observed at the first assessment.

RECIST v1.1 indicates Response Evaluation Criteria in Solid Tumors version 1.1.